Nearly 900 million adults worldwide live with obesity, a major risk factor for over 20 diseases, including diabetes, cardiovascular and neurological disorders. While GLP-1 receptor agonists offer treatment, they can cause muscle loss, suppress the reward system, and have high discontinuation rates. RNA interference (RNAi) therapy, conversely, precisely targets the messenger RNA (mRNA) of specific genes involved in metabolic pathways—including INHBE (SGB-7342), and other novel First-In-Class (FIC) targets. RNAi has potential to become a central component of obesity therapy. It drives selective fat loss, preserves lean muscle, and improves overall metabolic health without the side effects of existing treatments.
IgA Nephropathy (IgAN) and C3 Glomerulopathy (C3G) are severe kidney diseases characterized by dysregulated complement system activity, often resulting in end-stage renal disease. Current treatments are limited and have significant side effects. RNA interference (RNAi) therapy targets the messenger RNA (mRNA) of complement component 3 (SGB-9768) or complement factor B (SGB-3383), selectively inhibiting the complement pathway. This approach aims to reduce immune-mediated kidney injury in patients with IgAN, C3G, and other complement-mediated kidney diseases.
Phase 2 and Phase 3 trials in Asia will be conducted by Innovent and Phase 3 trials in the rest of the world will be conducted by SanegeneBio.
*IgAN: IgA Nephropathy; C3G:C3 Glomerulopathy; IC-MPGN: Immune Complex-Mediated Membranoproliferative Glomerulonephritis; PNH: Paroxysmal Nocturnal Hemoglobinuria; aHUS: atypical Hemolytic Uremic Syndrome; COPD: Chronic Obstructive Pulmonary Disease; HHT: Hereditary Hemorrhagic Telangiectasia; HMB: Heavy Menstrual Bleeding.
